Nadofaragene Firadenovec: First Approval

Nadofaragene firadenovec (nadofaragene firadenovec-vncg; Adstiladrin(®)) is a non-replicating adenoviral vector-based gene therapy developed by Ferring Pharmaceuticals for the treatment of high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). Nadofaragene...

Descripción completa

Detalles Bibliográficos
Autor principal: Lee, Arnold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
AdisInsight Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239371/
https://www.ncbi.nlm.nih.gov/pubmed/36856952
http://dx.doi.org/10.1007/s40265-023-01846-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239371/
https://www.ncbi.nlm.nih.gov/pubmed/36856952
http://dx.doi.org/10.1007/s40265-023-01846-z

Ejemplares similares